Trial Profile
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Basal Insulin Alone or in Addition to Oral Antidiabetes Drugs (OADs)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Sotagliflozin (Primary) ; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms SOTA-INS
- Sponsors Lexicon Pharmaceuticals; Sanofi
- 21 Jul 2020 Primary endpoint (Change in HbA1c (for sotagliflozin dose 2 200mg)) has been met, according to a Lexicon Pharmaceuticals Media Release.
- 21 Jul 2020 Primary endpoint (Change in HbA1c (for sotagliflozin dose 1 400mg and dose 200mg)) has been met, according to a Lexicon Pharmaceuticals Media Release.
- 21 Jul 2020 According to a Lexicon Pharmaceuticals Media Release, final results from this study will be preserved for upcoming medical congresses and publications.